Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan pharmacokinetics in healthy Japanese and non-Asian participants
NCT06715670Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zibotentan in Liver cirrhosis (LC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity, Area under concentration-curve from time 0 to the last quantifiable concentration and 1 more. Started Dec 2024; status: completed.
02
Drugs
zibotentan
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT06715670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715670.